IgA Tarpeyo denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for iga tarpeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denies Tarpeyo for Medical Necessity — and Why That Denial Is Appealable

UnitedHealthcare's medical-necessity denial for Tarpeyo (budesonide delayed-release capsules for IgA nephropathy) typically means the plan's reviewer concluded that the submitted clinical information did not satisfy each element of UHC's internally defined coverage criteria. In IgA nephropathy, common gaps that trigger this denial include: insufficient documentation of disease severity (e.g., proteinuria levels, kidney-function trajectory), absence of evidence that supportive care measures have been optimized, or an incomplete prior-treatment history.

This is an information-gap denial more often than a true eligibility problem. The clinical record almost always contains the facts needed to meet criteria — the challenge is presenting them in the structured format the reviewer needs to confirm each criterion is met.

## Your Federal Appeal Rights

• ACA §2719 / ERISA §503: You are entitled to at least one full internal appeal and, for non-grandfathered plans, binding external review by an Independent Review Organization.
• Right to the denial criteria: Under ERISA and ACA rules, UHC must provide, upon request, the specific clinical criteria used in the adverse determination. Obtain these before writing your appeal.
• Timeline: Internal appeal deadline is generally 180 days from the denial notice. External review is available for approximately four months after final internal denial. Expedited review (72-hour decision) is available when standard timing could seriously jeopardize kidney function.

## Documentation to Gather Before You Appeal

1. Diagnosis confirmation — biopsy report and nephrologist notes confirming primary IgA nephropathy; include any Oxford/MEST-C scoring if present in the pathology report. 2. Disease-severity markers — laboratory trend data (urine protein measurements, serum creatinine, eGFR trajectory) from the chart showing the clinical course over time. Do not summarize — attach actual lab reports with dates. 3. Prior and concurrent treatment history — complete list of supportive therapies tried (renin-angiotensin system blockade, blood pressure management, dietary interventions) with start dates, doses, duration, and documented outcomes or intolerances. 4. Prescriber medical-necessity letter — your nephrologist should write a letter that maps your clinical presentation directly to UHC's stated criteria and to the criteria in the FDA-approved prescribing label. 5. Relevant society guideline — your physician may note that the applicable nephrology society guideline supports treatment for patients with your disease profile (without citing specific numerical cutoffs).

## Criteria-Mapping Structure

Request UHC's coverage policy for Tarpeyo and extract every listed criterion. Build a two-column table: criterion text on the left, the specific chart finding or document reference that satisfies it on the right. Leave nothing unanswered. End with your nephrologist's attestation that, in their clinical judgment, the treatment is medically necessary for this patient based on the documented evidence.